HRP20181319T1 - Oslabljeni virusi koji su korisni kao cjepiva - Google Patents

Oslabljeni virusi koji su korisni kao cjepiva

Info

Publication number
HRP20181319T1
HRP20181319T1 HRP20181319TT HRP20181319T HRP20181319T1 HR P20181319 T1 HRP20181319 T1 HR P20181319T1 HR P20181319T T HRP20181319T T HR P20181319TT HR P20181319 T HRP20181319 T HR P20181319T HR P20181319 T1 HRP20181319 T1 HR P20181319T1
Authority
HR
Croatia
Prior art keywords
vaccines
attenuated viruses
viruses useful
useful
attenuated
Prior art date
Application number
HRP20181319TT
Other languages
English (en)
Inventor
Eckard Wimmer
Steve Skiena
Steffen Mueller
Bruce Futcher
Dimitris Papamichail
John Robert Coleman
Jeronimo Cello
Original Assignee
The Research Foundation Of The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181319(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Research Foundation Of The State University Of New York filed Critical The Research Foundation Of The State University Of New York
Publication of HRP20181319T1 publication Critical patent/HRP20181319T1/hr
Publication of HRP20181319T4 publication Critical patent/HRP20181319T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32761—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32761—Methods of inactivation or attenuation
    • C12N2770/32762—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20181319TT 2007-03-30 2008-03-31 Oslabljeni virusi koji su korisni kao cjepiva HRP20181319T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90938907P 2007-03-30 2007-03-30
US6866608P 2008-03-07 2008-03-07
PCT/US2008/058952 WO2008121992A2 (en) 2007-03-30 2008-03-31 Attenuated viruses useful for vaccines
EP08799746.6A EP2139515B2 (en) 2007-03-30 2008-03-31 Attenuated viruses useful for vaccines

Publications (2)

Publication Number Publication Date
HRP20181319T1 true HRP20181319T1 (hr) 2018-10-19
HRP20181319T4 HRP20181319T4 (hr) 2024-02-16

Family

ID=39808891

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181319TT HRP20181319T4 (hr) 2007-03-30 2008-03-31 Oslabljeni virusi koji su korisni kao cjepiva

Country Status (13)

Country Link
US (5) US9476032B2 (hr)
EP (3) EP4368202A3 (hr)
JP (2) JP5733976B2 (hr)
KR (1) KR101621100B1 (hr)
CN (1) CN103476425B (hr)
AU (1) AU2008232491B2 (hr)
BR (1) BRPI0809600B1 (hr)
CA (1) CA2682089C (hr)
DK (1) DK2139515T4 (hr)
HR (1) HRP20181319T4 (hr)
MX (2) MX2009010549A (hr)
PL (1) PL2139515T5 (hr)
WO (1) WO2008121992A2 (hr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368202A3 (en) 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
WO2010039649A2 (en) * 2008-10-03 2010-04-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus-based system for production of hepatitis c virus (hcv)
US8647637B2 (en) 2009-01-30 2014-02-11 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
JP2012519484A (ja) * 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
US20120269849A1 (en) * 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
EP2490268A1 (en) * 2011-02-03 2012-08-22 Imec Method for fabricating photovoltaic cells
EP2751260A2 (en) * 2011-09-02 2014-07-09 Westfälische Wilhelms-Universität Münster Live attenuated influenza virus
JP2015502158A (ja) * 2011-12-16 2015-01-22 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク 新規の弱毒化ポリオウイルス：ＰＶ−１Ｍｏｎｏ−ｃｒｅ−Ｘ
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
EP2969005B1 (en) 2013-03-15 2019-10-16 The Research Foundation for The State University of New York Attenuated influenza viruses and vaccines
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
CN104419687B (zh) * 2013-09-03 2017-03-15 中国农业大学 重组PRRS病毒HV‑nsp29及其应用
BR112017004452B1 (pt) 2014-09-05 2023-12-12 The Research Foundation For The State University Of New York Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
WO2017099801A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Compositions, kits, and methods to detect hiv virus
US10731227B2 (en) 2014-12-12 2020-08-04 The Trustees Of The University Of Pennsylvania Compositions, kits, and methods to detect HIV virus
EP3050962A1 (en) 2015-01-28 2016-08-03 Institut Pasteur RNA virus attenuation by alteration of mutational robustness and sequence space
CN107949636B (zh) * 2015-06-04 2021-11-09 香港大学 活减毒病毒以及生产和使用方法
EP3355899A4 (en) * 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
KR20180085730A (ko) 2015-10-29 2018-07-27 에모리 유니버시티 키메라 rsv, 면역원성 조성물, 및 사용 방법
CN105821009B (zh) * 2016-04-05 2019-07-26 中国人民解放军第三〇二医院 靶向肝癌溶瘤流感病毒的构建及其应用
WO2017218727A1 (en) 2016-06-15 2017-12-21 President And Fellows Of Harvard College Methods for rule-based genome design
WO2018017949A1 (en) * 2016-07-22 2018-01-25 Verily Life Sciences Llc Quantitative massively parallel proteomics
US11149255B2 (en) * 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
CN106650307B (zh) * 2016-09-21 2019-04-05 武汉伯远生物科技有限公司 一种基于密码子对使用频度的基因密码子优化方法
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
CN106520832B (zh) * 2016-11-17 2020-02-18 新乡医学院 双顺反子表达载体、表达系统、制备方法及应用
EP3548078A1 (en) * 2016-11-30 2019-10-09 Boehringer Ingelheim Animal Health USA Inc. Attenuated swine influenza vaccines and methods of making and use thereof
AR111770A1 (es) 2017-05-05 2019-08-21 Elanco Us Inc Vacuna para enfermedad respiratoria bovina
WO2019016680A1 (en) 2017-07-17 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF LYSSAVIRUS
WO2019126690A1 (en) * 2017-12-22 2019-06-27 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
CN108586608A (zh) * 2018-04-13 2018-09-28 四川农业大学 一种dhav-1 2c蛋白多克隆抗体、重组融合蛋白及其制备方法
CN109504662B (zh) * 2018-11-09 2022-06-10 浙江天元生物药业有限公司 一种柯萨奇病毒减毒株及其应用
BR112021010611A2 (pt) 2018-12-14 2021-08-24 Glaxosmithkline Biologicals S.A. Composições e métodos de vacina de reforço (prime boost) heterólogo
JP7517704B2 (ja) * 2019-06-21 2024-07-17 国立大学法人大阪大学 外来遺伝子を安定的に保持する人工組換えｒｎａウイルスの作製方法
TW202144570A (zh) * 2020-01-28 2021-12-01 美商科達金尼克斯有限公司 去最佳化(DEOPTIMIZED)SARS-CoV-2及其方法及用途
CN111321125B (zh) * 2020-02-03 2022-07-19 广州医科大学 重组流感病毒及其在疫苗中的应用
CN111269895B (zh) * 2020-02-03 2022-09-27 广州医科大学 甲型流感病毒减毒株及其作为骨架病毒和疫苗的应用
EP4125918A1 (de) * 2020-03-27 2023-02-08 Johannes Reinmüller Virustatisches mittel
CN111481663B (zh) * 2020-04-09 2022-12-09 广州医科大学 一种流感病毒活疫苗及其制备方法
US20230143228A1 (en) * 2020-04-21 2023-05-11 Emory University Coronavirus vaccines, compositions, and methods related thereto
EP4162030A4 (en) * 2020-05-27 2024-07-24 Us Agriculture LIVE ATTENUATED STRAINS OF FOOT-AND-MOUTH DISEASE MODIFIED BY DEOPTIMISATION AND USES THEREOF
BR112022024067A2 (pt) * 2020-05-27 2023-04-25 Us Agriculture Cepas vivas atenuadas de febre aftosa modificadas por desotimização e usos das mesmas
WO2022011032A1 (en) * 2020-07-07 2022-01-13 Codagenix Inc. Method of producing modified virus genomes and producing modified viruses
US20240252616A1 (en) * 2020-07-16 2024-08-01 Griffith University Live-attenuated virus vaccine
WO2022040355A2 (en) * 2020-08-19 2022-02-24 City Of Hope Lamp detection of sars-cov-2 in saliva for the rapid diagnosis of covid-19
CN112662633A (zh) * 2020-12-28 2021-04-16 中国水产科学研究院珠江水产研究所 II型草鱼呼肠孤病毒冷适应株GCRV-GD108ca及其应用
CA3223318A1 (en) * 2021-06-23 2022-12-29 Muhammad Munir Virus attenuation
US20230274791A1 (en) * 2021-11-29 2023-08-31 The Chinese University Of Hong Kong Codon de-optimization or optimization using genetic architecture
WO2024036331A2 (en) * 2022-08-12 2024-02-15 Fred Hutchinson Cancer Center Barcoded influenza viruses and mutational scanning libraries including the same
CN117153270B (zh) * 2023-10-30 2024-02-02 吉林华瑞基因科技有限公司 一种基因二代测序数据处理方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004147A1 (en) 1993-08-02 1995-02-09 Chiron Corp Recombinant constructs using replacement sequences in hypervariable regions
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US20040023327A1 (en) 1995-12-07 2004-02-05 Short Jay M. End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
GB9705669D0 (en) † 1997-03-19 1997-05-07 British Tech Group Attenuated polioviruses
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
WO1999007859A1 (en) * 1997-08-07 1999-02-18 Altwell Biotech. Inc. Replication-competent recombinant sabin type 1 strain of poliovirus
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
GB9817082D0 (en) † 1998-08-06 1998-10-07 Btg Int Ltd Attenuated poliovirus vaccine
IL140441A0 (en) 1998-09-29 2002-02-10 Maxygen Inc Shuffling of codon altered genes
EP1161529A2 (en) 1999-03-09 2001-12-12 Diversa Corporation End selection in directed evolution
EP1092041A4 (en) 1999-03-26 2001-09-19 Diversa Corp EXONUCLEASE-MEDIATED ASSEMBLY OF NUCLEIC ACIDS IN THE DIRECT EVOLUTION
CA2291367A1 (en) * 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CN1262665C (zh) 2000-07-21 2006-07-05 葛兰素集团有限公司 经过密码子最优化的乳头状瘤病毒序列
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US20050124010A1 (en) 2000-09-30 2005-06-09 Short Jay M. Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating
US20030041354A1 (en) 2000-10-17 2003-02-27 Novozymes A/S Transgenic plants
DK1340085T3 (da) 2000-10-17 2008-12-01 Besst Test Aps Assay til direkte detektion af en biologisk celle i en legemsvæskepröve
WO2002095363A2 (en) * 2001-05-25 2002-11-28 Tao Biosciences, Llc Methods for attenuation of virulence in bacteria
PT2311848E (pt) * 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
WO2005024012A1 (en) 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
US7951556B2 (en) 2004-04-07 2011-05-31 Novozymes A/S Mutated prokaryotic cells with high secretion-levels
DK1748790T3 (en) 2004-05-24 2015-10-19 Medimmune Llc Multiplasmidsystem for the production of influenza
JP2008504839A (ja) 2004-07-02 2008-02-21 ヘンリー， エル． ニーマン， コピーチョイス組換え及びその使用法
DE602005024694D1 (de) 2004-07-20 2010-12-23 Novozymes Inc Verfahren zur herstellung von mutierten polynukleotiden
WO2006015370A2 (en) 2004-08-03 2006-02-09 The Regents Of The University Of California Site specific system for generating diversity protein sequences
EP3312272B1 (en) * 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1945780B1 (en) 2005-10-14 2015-09-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Rabies virus vector systems and compositions and methods thereof
CN101563463B (zh) 2006-08-25 2013-03-27 美国国有健康与人类服务部(马里兰州) 修饰的安卡拉（mva）痘苗病毒基因的基因组中保守基因之间的基因间位点
EP2082047A2 (en) 2006-08-29 2009-07-29 Danisco US, INC., Genencor Division Compositions and methods for improved protein production
EP2082044B1 (en) 2006-10-24 2016-06-01 Basf Se Method of increasing gene expression using modified codon usage
US20100041107A1 (en) 2006-10-24 2010-02-18 Basf Se Method of reducing gene expression using modified codon usage
WO2008121487A2 (en) 2007-03-29 2008-10-09 The Govt. Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Sevices. Live attenuated virus vaccines for la crosse virus and other bunyaviridae
EP4368202A3 (en) * 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
US20120040367A1 (en) 2007-10-15 2012-02-16 The University Of Queensland Construct system and uses therefor
EP3355899A4 (en) 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
US11821111B2 (en) 2019-11-15 2023-11-21 Fred Hutchinson Cancer Center Barcoded influenza viruses and deep mutational scanning libraries including the same

Also Published As

Publication number Publication date
CA2682089A1 (en) 2008-10-09
JP2015091247A (ja) 2015-05-14
US20240228981A1 (en) 2024-07-11
US11162080B2 (en) 2021-11-02
US10023845B2 (en) 2018-07-17
JP5733976B2 (ja) 2015-06-10
KR101621100B1 (ko) 2016-05-13
CN103476425B (zh) 2015-07-15
MX349825B (es) 2017-08-15
US9476032B2 (en) 2016-10-25
AU2008232491B2 (en) 2014-05-22
US20190010469A1 (en) 2019-01-10
CN103476425A (zh) 2013-12-25
CA2682089C (en) 2019-03-12
US20170067030A1 (en) 2017-03-09
EP2139515A2 (en) 2010-01-06
US20220298492A1 (en) 2022-09-22
EP4368202A2 (en) 2024-05-15
WO2008121992A2 (en) 2008-10-09
EP2139515B1 (en) 2018-06-13
AU2008232491A1 (en) 2008-10-09
PL2139515T5 (pl) 2024-04-08
WO2008121992A3 (en) 2009-02-26
BRPI0809600B1 (pt) 2023-01-24
KR20100019423A (ko) 2010-02-18
HRP20181319T4 (hr) 2024-02-16
US20100209454A1 (en) 2010-08-19
JP2010523086A (ja) 2010-07-15
EP2139515A4 (en) 2011-07-06
EP3431099A1 (en) 2019-01-23
DK2139515T4 (da) 2024-03-04
EP4368202A3 (en) 2024-08-21
EP2139515B2 (en) 2023-12-20
BRPI0809600A2 (pt) 2016-07-12
DK2139515T3 (en) 2018-08-27
PL2139515T3 (pl) 2018-11-30
EP3431099B1 (en) 2024-01-03
MX2009010549A (es) 2010-03-15

Similar Documents

Publication Publication Date Title
PL2139515T3 (pl) Atenuowane wirusy przydatne w szczepionkach
EP2062246A4 (en) CHIMERIC VIRAL VACCINES
GB0822068D0 (en) Methods for virus design
GB0807424D0 (en) Virus
ZA201101481B (en) Vaccine
IL208660A0 (en) Coccididosis vaccines
HRP20151124T1 (en) Vaccine
GB0714578D0 (en) Viruses
GB0700135D0 (en) Vaccine
ZA201001029B (en) Vaccines
GB0822001D0 (en) Vaccine
GB0810710D0 (en) Vaccine
ZA201007402B (en) Vaccine
GB0816284D0 (en) Vaccine
GB0816447D0 (en) Vaccine
GB0710538D0 (en) Vaccine
GB0801326D0 (en) Vaccines
GB0823560D0 (en) Virus
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0810378D0 (en) Virus
GB0813823D0 (en) Virus
GB0703066D0 (en) Viruses
GB0818459D0 (en) Vaccines
GB0809781D0 (en) Vaccine
GB0802108D0 (en) Vaccine